Vaginal atrophy in obstetrician-gynecologist practice


Cite item

Abstract

Vaginal atrophy is a characteristic symptom of menopause, which can develop in young women as a result of temporary or permanent deficiency of estrogen, as well as after operations of the cervix or connective tissue diseases. Manifestations of diverse vaginal atrophy, affect sexuality and significantly reduce the quality of life of women. The diagnosis of vaginal atrophy is clinical and depends solely on the skill of the doctor who expertly evaluates medical history and examines, since patients with vaginal atrophy often do not complain. Estrogens are considered to be the most effective option for the treatment of all forms of vaginal atrophy in the local application. In Russia, it is only estriol - estrogen deprived of systemic metabolic effects and does not require monitoring of the endometrium and breast, as well as the additional use of progestogen to protect the endometrium - that is registered for the vaginal use. Estriol in the form of vaginal suppositories (Ovipol Clio®) can be used in women with urogenital atrophy in postmenopausal women with amenorrhea or in the reproductive age, in the treatment of stenosis of the cervical canal, or after unclear smear from the cervix to the background of vaginal atrophy, as well as in urology in relapsed urinary tract infection in young women or as a preoperative preparation for operations on the pelvic floor.

About the authors

I G Shestakova

ФГАОУ ВО Российский университет дружбы народов, Москва

Email: i_shestakova@yahoo.com
канд. мед. наук, доц. каф. акушерства, гинекологии и репродуктивной медицины фак. повышения квалификации медицинских работников

References

  1. Балан В.Е., Сметник В.П., Анкирская А.С. и др. Урогенитальные расстройства в климактерии. Медицина климактерия. Под ред. В.П.Сметник. М.: Литера, 2006; с. 217-90.
  2. Calleja-Agius J, Brincat M.P. Urogenital atrophy. Climacteric 2009; 12: 279-85.
  3. Радзинский В.Е., Хамошина М.Б., Мельникова Г.Г. Современный подход к терапии и профилактике метаболических нарушений, связанных с хирургической менопаузой. Доктор. Ру. Гинекология. Эндокринология. Ч. 1. Гинекология. 2009; 6 (50): 21-7.
  4. Woods N.F, Mitchell E.S. Symptoms during the perime no pause: prevalence, severity, trajectory, and significance in women's lives. Am J Med 2005; 118 (Suppl. 12B): 14.
  5. Nappi R.E, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010; 67: 233.
  6. Castelo-Branco C, Cancelo M.J, Villero J et al. Management of postmenopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005; 52 (Suppl. 1): S46.
  7. Capriello P, Barale E, Cappelli N et al. Teti G.Sjögren's syndrome: clinical, cytological, histological and colposcopic aspects in women. Clin Exp Obstet Gynecol 1988; 15 (1-2): 9-12.
  8. Nilsson K, Risberg B, Heimer G. The vaginal epithelium in the postmenopause - cytology, histology and pH as methods of assessment. Maturitas 1995; 21: 51.
  9. Baumgart J, Nilsson K, Stavreus-Evers A et al. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol 2011; 204: 26.
  10. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006; CD001500.
  11. Al-Baghdadi O, Ewies A.A. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up - to - date overview. Climacteric 2009; 12: 91-105.
  12. Raz R, Stamm W.E. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329: 753.
  13. Costantino D, Guaraldi C. Effectiveness and safety of vaginal suppositories for the treatment of the vaginal atrophy in postmenopausal women: an open, non - controlled clinical trial. Eur Rev Med Pharmacol Sci 2008; 12: 411.
  14. Winneker R.C, Harris H.A. Progress and prospects in treating postmenopausal vaginal atrophy. Clin Pharmacol Ther 2011; 89: 129.
  15. Al-Baghdadi O, Ewies A.A. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up - to - date overview. Climacteric 2009; 12: 91.
  16. Балан В.Е., Ковалева Л.А., Амирова Ж.С., Рафаэлян И.В. Возможности гормональной терапии урогенитальной атрофии у женщин. Акушерство и гинекология. 2011; 6: 113-6.
  17. Christianson M.S, Barker M.A, Lindheim S.R. Overcoming the challenging cervix: techniques to access the uterine cavity. J Low Genit Tract Dis 2008; 12 (1): 24-31.
  18. Pinggeraa G-M et al. Effects of local estrogen therapy on recurrent urinary tract infections in young females under oral contraceptives. European Urology, 2014.
  19. Пушкарь Д.Ю., Дьяков В.В., Годунов Б.Н., Гвоздев М.Ю. Овестин в подготовке к трансвагинальным операциям. Урология. 2002; 5: 34-6.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).